ACAD
ACADIA PHARMACEUTICALS INC
Nasdaq: ACAD · San Diego, CA · Healthcare
$21.80-0.29 (-1.31%)Closed
Market Cap$3.71B
Cash$177.7Mmost recent
Runwayprofitable
P/E (TTM)9.5EPS $2.30
52-Wk Range$14.35 – $28.06
Avg Volume1.9M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$21.80+28.3%
Pipeline
Drug candidates sponsored by ACADIA PHARMACEUTICALS · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | Pimavanserin | Parkinson Disease Psychosis+7 more | Completed | 2025-02-14past | 15 | |
| Phase 3 | pimavanserin tartrate | Parkinson's Disease Psychosis+1 more | Completed | 2016-09-28past | 3 | |
| Phase 3 | Pimavanserin tartrate (ACP-103) | Parkinson's Disease Psychosis | Completed | 2018-05-30past | 4 | |
| Phase 3 | Placebo | Dementia-related Psychosis | Completed | 2019-07-31past | 1 | |
| Phase 3 | Trofinetide | Rett Syndrome | Completed | 2023-06-30past | 4 | |
| Phase 2 | ACP-204 | Alzheimer's Disease Psychosis+1 more | Recruiting | 2028-01 | 4 | |
| Phase 3 | Carbetocin | Hyperphagia in Prader-Willi Syndrome | Active, not recruiting | 2029-05 | 2 | |
| Phase 2 | ACP-104 | Schizophrenia | Completed | 2008-02past | 1 | |
| Phase 2 | Pimavanserin 34 mg | Agitation and Aggression in Alzheimer's Disease | Terminated | 2018-01-25past | 1 | |
| Phase 2 | ACP-044 Dose A | Acute Postoperative Pain+2 more | Completed | 2022-10-06past | 2 | |
| Phase 2 | ACP-211 | Major Depressive Disorder (MDD)+1 more | Recruiting | 2027-08 | 1 | |
| Phase 2 | ACP-103 | Schizophrenia+3 more | Completed | — | 2 | |
| N/A | Unnamed | Parkinson Disease Psychosis | Terminated | 2021-03-08past | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for ACAD. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.